Literature DB >> 18258511

Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998.

Isabel Badell1, Arturo Muñoz, Jesús Estella, Rafael Fernández-Delgado, Germán Javier, Amparo Verdeguer, Josep Cubells.   

Abstract

INTRODUCTION: The first multi-centric protocol for childhood acute lymphoblastic leukaemia (ALL) treatment in Spain started in 1989 and was conducted by the Spanish Pediatric Hematology and Oncology Societies.
MATERIALS AND METHODS: A total of 673 patients were included in two consecutive trials, SHOP-89 (1989-1993) and SHOP- 94 (1994-1998). Approximately 67% of the children diagnosed with ALL in Spain during this period were enrolled in these trials. The 250 eligible patients enrolled in the SHOP- 89 study were stratified to either a standard or a high-risk group. Therapy schedule was based on the central nervous system (CNS) therapy designed by St Jude CRH and the Children's Cancer Group, and the post-induction intensification developed by the BFM group. In the SHOP-94 study, a further high-risk group was included in the stratification of the 423 enrolled patients. The therapeutic protocol was characterised by intensification of systemic chemotherapy and the administration of cranial radiotherapy only to patients at high risk of relapse or with CNS involvement at diagnosis.
RESULTS: Event-free survival (EFS) increased from 0.57+/- 0.03 at 15 years in SHOP-89, to 0.68+/-0.03 at 11 years in SHOP-94 (p=0.01). Relapse rate decreased from SHOP-89 to SHOP-94: 0.38 vs. 0.25 (p=0.01). CNS relapse rate was 9.1% in SHOP-89 and 4.6% in SHOP-94 (p=0.001). EFS in patients with T-immunophenotype was 0.40+/-0.08 in SHOP-89 and 0.44+/-0.06 in SHOP-94 (p=ns).
CONCLUSIONS: Our therapeutic results evidence a significant improvement in EFS and systemic and CNS relapse rates among the two consecutive trials after modification of patient stratification and intensification of systemic chemotherapy.

Entities:  

Mesh:

Year:  2008        PMID: 18258511     DOI: 10.1007/s12094-008-0165-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  21 in total

1.  Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.

Authors:  G Paolucci; V Vecchi; C Favre; R Miniero; E Madon; A Pession; R Rondelli; G De Rossi; L Lo Nigro; F Porta; N Santoro; P Indolfi; G Basso; V Conter; M Aricò
Journal:  Haematologica       Date:  2001-05       Impact factor: 9.941

2.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia.

Authors:  R J Aur; J Simone; H O Hustu; T Walters; L Borella; C Pratt; D Pinkel
Journal:  Blood       Date:  1971-03       Impact factor: 22.113

3.  Treatment of childhood acute lymphocytic leukemia.

Authors:  D Pinkel
Journal:  J Pediatr       Date:  1970-12       Impact factor: 4.406

4.  [The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)].

Authors:  G Henze; H J Langermann; J Brämswig; H Breu; H Gadner; G Schellong; K Welte; H Riehm
Journal:  Klin Padiatr       Date:  1981-05       Impact factor: 1.349

5.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

Authors:  P S Gaynon; M E Trigg; N A Heerema; M G Sensel; H N Sather; G D Hammond; W A Bleyer
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

6.  Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

Authors:  O B Eden; G Harrison; S Richards; J S Lilleyman; C C Bailey; J M Chessells; I M Hann; F G Hill; B E Gibson
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

7.  Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991.

Authors:  W A Kamps; A J Veerman; E R van Wering; J F van Weerden; R Slater; A van der Does-van den Berg
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

8.  Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995.

Authors:  V Conter; M Aricò; M G Valsecchi; G Basso; A Biondi; E Madon; F Mandelli; G Paolucci; A Pession; C Rizzari; R Rondelli; L Zanesco; G Masera
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

Review 9.  Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.

Authors:  Giovanni Cazzaniga; Andrea Biondi
Journal:  Haematologica       Date:  2005-03       Impact factor: 9.941

10.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Authors:  M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

View more
  1 in total

1.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

Authors:  Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.